Uses of Duvelisib

Duvelisib is a concomitant inhibitor of isoforms and gamma isotopes, which may induce a broad spectrum of innate and adaptive immunosuppressive activity. It is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who develop small lymphocytic lymphoma after at least 2 previous treatments.

Duvelisib, also known as IPI-145 and INK-1197, is a kinase inhibitor. Kinase is an enzyme that promotes cell growth. Duvelisib is a concomitant inhibitor of isoforms and gamma isotopes, which may induce a broad spectrum of innate and adaptive immunosuppressive activity. Duvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia and patients with small-cell lymphoma after at least 2 previous treatments. Duvelisib is available in soft capsule form.

With the mechanism of action being cytotoxic at micromolar doses and antagonizing the activation of downstream signaling even in the presence of mutations in BTK C481S, Duvelisib is indicated for treatment in specific cases such as: following:
Adult patient with recurrent or refractory chronic lymphocytic leukemia; Adult patients with recurrent or refractory follicular lymphoma; Patients with small lymphocytic lymphoma after at least 2 previous treatments.

Patients with a history of allergy or hypersensitivity to any of the ingredients in Duvelisib; Women who are planning to become pregnant, are pregnant or are breastfeeding; Men who are planning to have children.

Duvelisib is made in the form of softgels and is used orally, twice a day. Alcohol should not be consumed while taking Duvelisib.
If you forget to take a dose of Duvelisib, take it as soon as you remember. However, if it is almost time for your next dose of Duvelisib, skip the missed dose and take your next dose exactly as directed by your doctor. Never take a double dose of Duvelisib to make up for a missed dose.

Duvelisib medicine can cause many unwanted effects for users. The specific side effects of Duvelisi b are as follows:
Infection, decreased white blood cell count: Duvelisib can cause life-threatening infections in the patient. Tell your doctor right away if you have a fever, cough, sore throat, trouble breathing, burning when urinating; Diarrhea and enteritis: Diarrhea is one of the common undesirable effects of Duvelisib drug; Rash and skin reactions such as pain, ulceration, peeling of the skin; Pneumonia; Pain, aching muscles, joints; Anemia, decreased red blood cell count, fatigue; Nausea, vomiting; Electrolyte disorders: The use of Duvelisib can affect the normal levels of electrolytes such as potassium, phosphorus, sodium, calcium, ... in the body. It is necessary to closely monitor the electrolyte indicators in patients who are assigned to use Duvelisib; Increased liver toxicity, jaundice, yellow eyes, dark urine; Menstrual cycle irregularities, irregular sperm production or cessation of production in men.

Duvelisib blood levels can be affected by certain foods and medications. Duvelisib can interact with some drugs and foods as follows:
Grapefruit, grapefruit juice; Nelfinavir: When used in combination with Nelfinavir, the metabolism of Duvelisib may be reduced; Indinavir: When used in combination with Indinavir, the metabolism of Duvelisib may be reduced; Doxycycline drugs: When used in combination with the drug Doxycycline the metabolism of the drug Duvelisib may decrease; Clotrimazole drug: When used in combination with the drug Clotrimazole the metabolism of the drug Duvelisib may decrease; Drugs Terfenadin: When used in combination with drugs Terfenadin the metabolism of the drug Duvelisib may decrease; Ritonavir: When used in combination with Ritonavir, the metabolism of Duvelisib may be reduced; In addition, the metabolism of duvelisib drug may decrease when used in combination with drugs such as Voriconazole, Efavirenz, Ergotamine, Ketoconazole, Naloxone, Clarithromycin,....

Store Duvelisib at room temperature, in a cool, dry place, away from light and reach of children. Duvelisib is used to treat adult patients with relapsed or refractory chronic lymphocytic leukemia, patients with small lymphocytic lymphoma after at least 2 previous treatments. To use Duvelisib safely and effectively, patients need to take it exactly as prescribed by their doctor.

Reference source: oncolink.org